Total Payments
$5,394
2024 Payments
$110.62
Companies
32
Transactions
351
Medicare Patients
11,402
Medicare Billing
$2.0M
Payment Breakdown by Category
Food & Beverage$5,353 (99.2%)
Education$41.61 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,353 | 344 | 99.2% |
| Education | $41.61 | 7 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $522.59 | 33 | $0 (2024) |
| Merck Sharp & Dohme LLC | $494.41 | 32 | $0 (2023) |
| Amgen Inc. | $488.16 | 30 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $472.34 | 33 | $0 (2022) |
| ABBVIE INC. | $433.94 | 27 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $421.86 | 33 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $406.92 | 26 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $405.96 | 27 | $0 (2022) |
| Novo Nordisk Inc | $376.40 | 23 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $290.27 | 15 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $110.62 | 6 | ABBVIE INC. ($41.36) |
| 2023 | $336.42 | 20 | AbbVie Inc. ($170.31) |
| 2022 | $610.86 | 38 | ABBVIE INC. ($172.93) |
| 2021 | $1,026 | 68 | Janssen Pharmaceuticals, Inc ($159.10) |
| 2020 | $672.34 | 44 | Amgen Inc. ($143.44) |
| 2019 | $1,108 | 74 | AstraZeneca Pharmaceuticals LP ($189.71) |
| 2018 | $370.00 | 25 | PFIZER INC. ($69.55) |
| 2017 | $1,160 | 76 | SANOFI-AVENTIS U.S. LLC ($257.84) |
All Payment Transactions
351 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/07/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: NEUROSCIENCE | ||||||
| 05/01/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.20 | General |
| Category: NEUROSCIENCE | ||||||
| 02/16/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: PAIN | ||||||
| 01/24/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: Psychology/Psychiatric | ||||||
| 01/04/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: PAIN | ||||||
| 10/18/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.55 | General |
| Category: NEUROSCIENCE | ||||||
| 10/17/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/11/2023 | Avion Pharmaceuticals | NP Thyroid 60 (Drug) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: Hyperthyroidism | ||||||
| 09/14/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: NEUROSCIENCE | ||||||
| 08/22/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $5.00 | General |
| Category: NEUROSCIENCE | ||||||
| 08/08/2023 | AbbVie Inc. | VRAYLAR (Drug) | Education | In-kind items and services | $8.45 | General |
| Category: NEUROSCIENCE | ||||||
| 08/01/2023 | Supernus Pharmaceuticals, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 06/13/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.84 | General |
| Category: DIABETES | ||||||
| 06/12/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.94 | General |
| Category: NEUROSCIENCE | ||||||
| 06/06/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.33 | General |
| Category: NEUROSCIENCE | ||||||
| 05/17/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $33.77 | General |
| Category: NEUROSCIENCE | ||||||
| 05/02/2023 | Merck Sharp & Dohme LLC | STEGLATRO (Drug), SEGLUROMET, STEGLUJAN | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: ENDOCRINOLOGY | ||||||
| 04/21/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.78 | General |
| Category: NEUROSCIENCE | ||||||
| 04/19/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $6.01 | General |
| Category: NEUROSCIENCE | ||||||
| 04/06/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $7.89 | General |
| Category: NEUROSCIENCE | ||||||
| 03/24/2023 | Merck Sharp & Dohme LLC | STEGLATRO (Drug), VERQUVO, SEGLUROMET | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: ENDOCRINOLOGY | ||||||
| 03/13/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: DIABETES | ||||||
| 03/07/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.08 | General |
| Category: NEUROSCIENCE | ||||||
| 02/21/2023 | PFIZER INC. | COMIRNATY (Biological), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: VACCINES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 2,618 | 29,726 | $983,421 | $513,747 |
| 2022 | 25 | 2,957 | 30,770 | $988,078 | $517,005 |
| 2021 | 25 | 2,895 | 27,018 | $965,253 | $523,491 |
| 2020 | 27 | 2,932 | 28,780 | $986,497 | $457,764 |
Total Patients
11,402
Total Services
116,294
Medicare Billing
$2.0M
Procedure Codes
97
All Medicare Procedures & Services
97 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 453 | 4,393 | $474,444 | $268,034 | 56.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 419 | 1,923 | $299,988 | $162,322 | 54.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 45 | 256 | $39,424 | $22,966 | 58.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 184 | 330 | $21,450 | $12,991 | 60.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 47 | 65 | $19,370 | $8,404 | 43.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 127 | 705 | $21,150 | $6,605 | 31.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 77 | 111 | $10,323 | $5,203 | 50.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 47 | 65 | $6,955 | $3,935 | 56.6% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2023 | 128 | 128 | $3,840 | $3,734 | 97.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 126 | 126 | $3,780 | $3,585 | 94.8% |
| 90670 | Pneumococcal vaccine, 13-valent | Office | 2023 | 14 | 14 | $3,500 | $3,430 | 98.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 29 | 29 | $8,700 | $3,044 | 35.0% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 250 | 2,019 | $30,285 | $2,239 | 7.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $4,266 | $1,769 | 41.5% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 202 | 3,779 | $11,340 | $1,420 | 12.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 64 | 282 | $2,538 | $1,331 | 52.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 226 | 14,132 | $14,132 | $1,277 | 9.0% |
| 81003 | Automated urinalysis test | Office | 2023 | 76 | 277 | $2,216 | $605.26 | 27.3% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 72 | 1,060 | $5,300 | $452.18 | 8.5% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 14 | 14 | $420.00 | $401.52 | 95.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 451 | 2,398 | $374,088 | $214,925 | 57.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 462 | 3,505 | $378,540 | $209,420 | 55.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 76 | 301 | $46,354 | $23,317 | 50.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 67 | 81 | $24,138 | $12,115 | 50.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 146 | 846 | $25,380 | $8,288 | 32.7% |
About Dr. Robi Chatterji, M.D
Dr. Robi Chatterji, M.D is a Family Medicine healthcare provider based in Enid, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750322459.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robi Chatterji, M.D has received a total of $5,394 in payments from pharmaceutical and medical device companies, with $110.62 received in 2024. These payments were reported across 351 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($5,353).
As a Medicare-enrolled provider, Chatterji has provided services to 11,402 Medicare beneficiaries, totaling 116,294 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 97 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Enid, OK
- Active Since 06/10/2006
- Last Updated 10/30/2014
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1750322459
Products in Payments
- FARXIGA (Drug) $441.63
- XARELTO (Drug) $405.96
- JARDIANCE (Drug) $328.65
- Aimovig (Biological) $327.51
- JANUVIA (Drug) $266.15
- PRALUENT (Drug) $250.37
- Ozempic (Drug) $202.84
- NURTEC ODT (Drug) $199.53
- QULIPTA (Drug) $198.70
- ELIQUIS (Drug) $192.55
- VRAYLAR (Drug) $167.54
- CHANTIX (Drug) $166.92
- BELSOMRA (Drug) $163.95
- BROVANA (Drug) $137.20
- UTIBRON (Drug) $117.85
- TROKENDI XR (Drug) $104.87
- BYSTOLIC (Drug) $88.83
- Victoza (Drug) $83.28
- VIAGRA (Drug) $79.56
- UBRELVY (Drug) $78.98
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Enid
Renah Gibson, Do, DO
Family Medicine — Payments: $6,775
Family Medicine $6,775
Charles Jantzen, Do, DO
Family Medicine — Payments: $5,706
Family Medicine $5,706
Jonathan Bushman, Do, DO
Family Medicine — Payments: $4,277
Family Medicine $4,277
Samantha Moery, D.o, D.O
Family Medicine — Payments: $4,099
Family Medicine $4,099
Dr. Richard Rivers, Md, MD
Family Medicine — Payments: $3,367
Family Medicine $3,367
Dr. Barbara Whinery, Md, MD
Family Medicine — Payments: $2,686
Family Medicine $2,686